<DOC>
	<DOC>NCT02377206</DOC>
	<brief_summary>The purpose of this study is to assess the level of neuroinflammation in Alzheimer Disease subject (mild to moderate) estimated with Binding Potential (BP) of [18F]DPA-714, and its relationship with the kinetics of cognitive decline over a 24-month follow-up period (as assessed by Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and Mini-Mental State Examination (MMSE) scores).</brief_summary>
	<brief_title>Neuroinflammation and Cognitive Decline in Alzheimer Disease</brief_title>
	<detailed_description>The purpose of this study is to assess the level of neuroinflammation in Alzheimer Disease subject (mild to moderate) estimated with Binding Potential (BP) of [18F]DPA-714 , and its relationship with the kinetics of cognitive decline over a 24-month follow-up period (as assessed by ADAS-Cog and MMSE scores). (DPA-714 : N,N-diethyl-2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide)</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Informed consent Age between 60 and 85 year (included) necessary knowledge of French (write and oral) to do neuropsychological tests Study level upper (or equal) than 7 year (considering first year of grammarschool as start) People with Alzheimer Disease defined as National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) standards : Light to mild AD defined by MiniMental State Examination (MMSE) score between 15 and 25 (included) Social security affiliation. MMSE score lower than 15 and upper or equal to 26 Evolutive disease which could possibly had consequences on central nervous system Inflammatory disease or evolutive neoplasia and/or C reactive protein (CRP) upper than 10mg/L Chronic use of alchohol and/or drug Serious depression defined by Montgomery Asberg Depression Rating Scale (MADRS) score higher than 18 Surgical or medical condition in the last 3 months Long term treatment which could possibly interfere with inflammatory process (especially the month before PET [18F]DPA714 imaging). Treatment by NMethylDAspartate antagonist Treatment by Minocycline Treatment by benzodiazepine (especially the month before PET [18F]DPA714 imaging) (Zolpidem, zopiclone and loprazolam excepted) Anomaly at neurological examination which is not a classical symptom Contraindication to magnetic resonance imaging (RMI) Florbetapir[18F] hypersensibility Participation to an other experimental protocol with drug. people under guardianship</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>PET</keyword>
	<keyword>[18F]DPA-714</keyword>
	<keyword>cognitive decline</keyword>
</DOC>